id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285955-fzm6036f	Nasir, N.	Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist Tocilizumab: a tertiary care experience from Pakistan	2020-06-26		.txt	text/plain	2057	130	46	Cytokine release syndrome in COVID-19 is characterized by hyperinflammation which manifests as ARDS, multi-organ failure, and high inflammatory parameters. We conducted a retrospective descriptive study from Feb 2020 to May 2020 on COVID-19 patients with ARDS and hyperinflammation characterized by raised CRP and/or ferritin. While limited studies from China have shown improved outcomes in COVID-19 patients with hyperinflammation and ARDS 9 , a study from Italy did not show significant mortality benefit 10 . Hence, we would like to report our clinical experience of the management of ARDS and hyperinflammation with the IL-6 inhibitor Tocilizumab which will be the first from a lower-middle-income country (LMIC). We conducted an observational study describing patient outcomes in those critically ill patients of COVID-19 who received tocilizumab intravenously for hyperinflammation and ARDS. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality	./cache/cord-285955-fzm6036f.txt	./txt/cord-285955-fzm6036f.txt